Photodynamic therapy of melanoma using new, synthetic porphyrins and phthalocyanines as photosensitisers - a comparative study

Clujul Medical

Volumn 88, Issue 2, 2015, Pages 175-180

  Baldea, Ioana ^a   Ion, Rodica Mariana ^b,c   Olteanu, Diana Elena ^a   Nenu, Iuliana ^a   Tudor, Diana ^a   Filip, Adriana Gabriela ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b NATIONAL RESEARCH AND DEVELOPMENT INSTITUTE FOR CHEMISTRY AND PETROCHEMISTRY ICECHIM   (Romania)

^c VALAHIA UNIVERSITY OF TARGOVISTE   (Romania)

Author keywords

Cell photokilling; Melanoma; Photodyamic therapy; Phthalocyanines; Porphyrins

Indexed keywords

EID: 84929411462     PISSN: 12222119     EISSN: 20668872     Source Type: Journal    
DOI: 10.15386/cjmed-419     Document Type: Article

References (41)

1. NCCN Guidelines Version 4. 2014 Melanoma. 2014. Available from:http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf.
2. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-6206.
3. Monge-Fuentes V, Muehlmann LA, de Azevedo RB. Perspectives on the application of nanotechnology in photodynamic therapy for the treatment of melanoma. Nano Rev. 2014;5.
4. Maduray K, Karsten A, Odhav B, Nyokong T. In vitro toxicity testing of zinc tetrasulfophthalocyanines in fibroblast and keratinocyte cells for the treatment of melanoma cancer by photodynamic therapy. J Photochem Photobiol B. 2011;103(2):98-104.
5. Robertson CA, Abrahamse H, Evans D. The in vitro PDT efficacy of a novel metallophthalocyanine (MPc) derivative and established 5-ALA photosensitizing dyes against human metastatic melanoma cells. Lasers Surg Med. 2010;42(10):766-776.
6. Haddad R, Blumenfeld A, Siegal A, Kaplan O, Cohen M, Skornick Y, et al. In vitro and in vivo effects of photodynamic therapy on murine malignant melanoma. Ann Surg Oncol. 1998;5(3):241-247.
7. Haddad R, Kaplan O, Greenberg R, Siegal A, Skornick Y, Kashtan H. Photodynamic therapy of murine colon cancer and melanoma using systemic aminolevulinic acid as a photosensitizer. Int J Surg Investig. 2000;2(3):171-178.
8. Szurko A, Kramer-Marek G, Widel M, Ratuszna A, Habdas J, Kus P. Photodynamic effects of two water soluble porphyrins evaluated on human malignant melanoma cells in vitro. Acta Biochim Pol. 2003;50(4):1165-1174.
9. Barge J, Decreau R, Julliard M, Hubaud JC, Sabatier AS, Grob JJ, et al. Killing efficacy of a new silicon phthalocyanine in human melanoma cells treated with photodynamic therapy by early activation of mitochondrion-mediated apoptosis. Exp Dermatol. 2004;13(1):33-44.
10. Saczko J, Kulbacka J, Chwilkowska A, Drag-Zalesiniska M, Wysocka T, Lugowski M, et al. The influence of photodynamic therapy on apoptosis in human melanoma cell line. Folia Histochem Cytobiol. 2005;43(3):129-132.
11. Mroz P, Huang YY, Szokalska A, Zhiyentayev T, Janjua S, Nifli AP, et al. Stable synthetic bacteriochlorins overcome the resistance of melanoma to photodynamic therapy. FASEB J. 2010;24(9):3160-3170.
12. Teng IT, Chang YJ, Wang LS, Lu HY, Wu LC, Yang CM, et al. Phospholipid-functionalized mesoporous silica nanocarriers for selective photodynamic therapy of cancer. Biomaterials. 2013;34(30):7462-7470.
13. Shi J, Yu X, Wang L, Liu Y, Gao J, Zhang J, et al. PEGylated fullerene/iron oxide nanocomposites for photodynamic therapy, targeted drug delivery and MR imaging. Biomaterials. 2013;34(37):9666-9677.
14. Chu M, Li H, Wu Q, Wo F, Shi D. Pluronic-encapsulated natural chlorophyll nanocomposites for in vivo cancer imaging and photothermal/photodynamic therapies. Biomaterials. 2014;35(29):8357-8373.
15. Camerin M, Magaraggia M, Soncin M, Jori G, Moreno M, Chambrier I, et al. The in vivo efficacy of phthalocyanine-nanoparticle conjugates for the photodynamic therapy of amelanotic melanoma. Eur J Cancer. 2010;46(10):1910-1918.
16. Idris NM, Gnanasammandhan MK, Zhang J, Ho PC, Mahendran R, Zhang Y. In vivo photodynamic therapy using upconversion nanoparticles as remote-controlled nanotransducers. Nat Med. 2012;18(10):1580-1585.
17. Tammela T, Saaristo A, Holopainen T, Yla-Herttuala S, Andersson LC, Virolainen S, et al. Photodynamic ablation of lymphatic vessels and intralymphatic cancer cells prevents metastasis. Sci Transl Med. 2011;3(69):69ra11.
18. Dabrowski JM, Urbanska K, Arnaut LG, Pereira MM, Abreu AR, Simões S, et al. Biodistribution and photodynamic efficacy of a water-soluble, stable, halogenated bacteriochlorin against melanoma. ChemMedChem. 2011;6(3):465-475.
19. Arnaut LG, Pereira MM, Dabrowski JM, Silva EF, Schaberle FA, Abreu AR, et al. Photodynamic therapy efficacy enhanced by dynamics: the role of charge transfer and photostability in the selection of photosensitizers. Chemistry. 2014;20(18):5346-5357.
20. Rapozzi V, Zorzet S, Zacchigna M, Drioli S, Xodo LE. The PDT activity of free and pegylated pheophorbide a against an amelanotic melanoma transplanted in C57/BL6 mice. Invest New Drugs. 2013;31(1):192-199.
21. Sheleg SV, Zhavrid EA, Khodina TV, Kochubeev GA, Istomin YP, Chalov VN, et al. Photodynamic therapy with chlorin e(6) for skin metastases of melanoma. Photodermatol Photoimmunol Photomed. 2004;20(1):21-26.
22. Donaldson MJ, Lim L, Harper CA, Mackenzie J, G Campbell W. Primary treatment of choroidal amelanotic melanoma with photodynamic therapy. Clin Experiment Ophthalmol. 2005;33(5):548-549.
23. Soucek P, Cihelkova I. Photodynamic therapy with verteporfin in subfoveal amelanotic choroidal melanoma (A controlled case). Neuro Endocrinol Lett. 2006;27(1-2):145-148.
24. Barbazetto IA, Lee TC, Rollins IS, Chang S, Abramson DH. Treatment of choroidal melanoma using photodynamic therapy. Am J Ophthalmol. 2003;135(6):898-899.
25. Baldea I, Filip AG. Photodynamic therapy in melanoma--an update. J Physiol Pharmacol. 2012;63(2):109-118.
26. Garland MJ, Cassidy CM, Woolfson D, Donnelly RF. Designing photosensitizers for photodynamic therapy: strategies, challenges and promising developments. Future Med Chem. 2009;1(4):667-691.
27. Ion RM, Nyokong T. The use of phthalocyanines and related complexes in photodynamic therapy. In: T.Nyokong, Ahsen V, eds. Photosensitizers in Medicine, Environment, and Security. 1st ed.: Springer . 2012.
28. Ion RM. Derivative UV-Vis spectrophotometry for porphyrins interactions in photodynamic therapy. Anal Lett. 2010;43(7):1277-1286.
29. Nowis D, Makowski M, Stoklosa T, Legat M, Issat T, Golab J. Direct tumor damage mechanisms of photodynamic therapy. Acta Biochim Pol. 2005;52:339-352.
30. Lindsey JS, Hsu HC, Schreiman IC. Synthesis of Tetraphenylporphyrins Under Very Mild Conditions. Tetrahedron Lett. 1986;27, 4969-4970.
31. Kashino G, Liu Y, Suzuki M, Masunaga S, Kinashi Y, Ono K, et al. An alternative mechanism for radioprotection by dimethyl sulfoxide; possible facilitation of DNA double-strand break repair. J Radiat Res. 2010;51:733-740.
32. Baldea I, Costin GE, Shellman Y, Kechris K, Olteanu ED, Filip A, et al. Biphasic pro-melanogenic and pro-apoptotic effects of all-trans-retinoic acid (ATRA) on human melanocytes: time-course study. J Dermatol Sci. 2013;72:168-76.
33. Kolarova H, Nevrelova P, Bajgar R, Jirova D, Kejlova K, Strnad M. In vitro photodynamic therapy on melanoma cell lines with phthalocyanine. Toxicol In Vitro. 2007;21:249-253.
34. Decreau R, Richard MJ, Verrando P, Chanon M, Julliard M. Photodynamic activities of silicon phthalocyanines against achromic M6 melanoma cells and healthy human melanocytes and keratinocytes. J Photochem Photobiol B. 1999;48:48-56.
35. Michailov N, Peeva M, Angelov I, Wohrle D, Muller S, Jori G, et al. Fluence rate effects on photodynamic therapy of B16 pigmented melanoma. J Photochem Photobiol B. 1997; 37154-157.
36. Friso E, Roncucci G, Dei D, Soncin M, Fabris C, Chiti G, et al. A novel 10B-enriched carboranyl-containing phthalocyanine as a radio- and photo-sensitising agent for boron neutron capture therapy and photodynamic therapy of tumours: in vitro and in vivo studies. Photochem Photobiol Sci. 2006;5:39-50.
37. Jiang XJ, Huang JD, Zhu YJ, Tang FX, Ng DK, Sun JC. Preparation and in vitro photodynamic activities of novel axially substituted silicon (IV) phthalocyanines and their bovine serum albumin conjugates. Bioorg Med Chem Lett. 2006; 16:2450-2453.
38. Cicillini SA, Prazias ACL, Tedesco AC, Serra OA, da Silva RS. Nitric oxide and singlet oxygen photo-generation by light irradiation in the phototherapeutic window of a nitrosyl ruthenium conjugated with a phthalocyanine rare earth complex. Polyhedron. 2009; 28:2766-2770.
39. Busetti A, Soncin M, Jori G, Rodgers MA. High efficiency of benzoporphyrin derivative in the photodynamic therapy of pigmented malignant melanoma. Br J Cancer. 1999;79:821-824.
40. Abels C, Fritsch C, Bolsen K, Szeimies RM, Ruzicka T, Goerz G, et al. Photodynamic therapy with 5-aminolaevulinic acid-induced porphyrins of an amelanotic melanoma in vivo. J Photochem Photobiol B. 1997;40:76-83.
41. Swavey S, Tran M. Porphyrin and Phthalocyanine Photosensitizers as PDT Agents: A New Modality for the Treatment of Melanoma, Recent Advances in the Biology, Therapy and Management of Melanoma, Dr. Lester Davids (Ed.), 2013. Available from: http://www.intechopen.com/books/recent-advances-in-the-biology-therapy-and-management-of-melanoma/porphyrin-and-phthalocyanine-photosensitizers-as-pdt-agents-a-new-modality-for-the-treatment-of-melanoma.